<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00299377</url>
  </required_header>
  <id_info>
    <org_study_id>1-Thiele</org_study_id>
    <nct_id>NCT00299377</nct_id>
  </id_info>
  <brief_title>Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI</brief_title>
  <official_title>Randomized Comparison of Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI and Effects on Infarct Size and Microvascular Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <brief_summary>
    <textblock>
      Randomized comparison of abciximab i.v. versus i.c. in patients with STEMI undergoing primary
      PCI. The hypothesis is, that higher concentration of abciximab i.c. leads to improved
      epicardial flow, perfusion, reduction of no-reflow, reduction in infarct size and
      subsequently better outcome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date>November 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size and microvascular obstruction assessed by MRI</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>ST-segment resolution, TIMI-Flow, TIMI blush grade, ejection fraction, left ventricular volumes, clinical outcome (MACE)</measure>
  </secondary_outcome>
  <enrollment>150</enrollment>
  <condition>Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab i.v.</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab i.c.</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical symptoms:

               -  Angina &lt; 12 h persistent Angina &gt; 30 min.

          2. ECG-Criteria:

               -  ST-elevation &gt; 1mm in ≥ 2 extremity leads

               -  ST-elevation &gt; 2mm in ≥ 2 contiguous anterior leads

          3. Informed consent

        Exclusion Criteria:

          1. No consent

          2. Pregnancy

          3. Allergy against abciximab, ASA or heparin

          4. Active peptic ulcus ventriculi or duodeni

          5. Active non-superficial bleeding

          6. Major surgical intervention, intracerebral interventions, puncture central artery &lt; 4
             weeks

          7. Active internal bleeding

          8. Cerebrovascular complications &lt; 2 years

          9. Known coagulation disorders, thrombocytopenia

         10. Arteriovenous malformations or aneurysms

         11. Severe Liver or renal dysfunction

         12. Severe untreated hypertension

         13. Active vasculitis

         14. Previous thrombolysis &lt; 12 h
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holger Thiele</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heartcenter Leipzig GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Leipzig - Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2006</study_first_submitted>
  <study_first_submitted_qc>March 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2006</study_first_posted>
  <last_update_submitted>July 2, 2008</last_update_submitted>
  <last_update_submitted_qc>July 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2008</last_update_posted>
  <keyword>STEMI</keyword>
  <keyword>infarct size</keyword>
  <keyword>primary PCI</keyword>
  <keyword>no-reflow</keyword>
  <keyword>ST-elevation myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

